On April 28, 2025, the U.S. Environmental Protection Agency (EPA) outlined upcoming Agency action to address per- and polyfluoroalkyl substances (PFAS). According to EPA’s announcement, “[i]n line with Administrator Zeldin’s Powering the Great American Comeback initiative, EPA’s work in this space will advance Pillar 1: Clean Air, Land, and Water for Every American, and Pillar 3: Permitting Reform, Cooperative Federalism, and Cross-Agency Partnership.” EPA states that these actions “are guided by the following principles: strengthening the science, fulfilling statutory obligations and enhancing communication, and building partnerships.” EPA plans additional actions and decisions across its program offices to help communities impacted by PFAS contamination. Below are the actions outlined on April 28, 2025, as well as links to our memoranda and blogs for more information.

Strengthening the Science 

Fulfilling Statutory Obligations and Enhancing Communication

Building Partnerships

Commentary

EPA’s continued “all of EPA” approach is welcome news. PFAS continues to be a significant issue that drives public concern. EPA is likely to continue to approach PFAS organized in several chemical category bins: medium- and long-chain perfluorocarboxylates and perfluorosulfonates and substances that degrade into them, short-chain PFAS, fluoropolymers, fluorinated gases, and other substances. Each bin represents a different potential for risk because of the extraordinary breadth of properties and toxicities between and among PFAS. This is in marked contrast to states that define PFAS so broadly that there are some members that contain only a single fluorine and include PFAS that are not persistent or bioaccumulative. Some states seem to be taking a more measured approach, like New Mexico, but it remains to be seen if this is a trend or exception.

We remain concerned that EPA is relying on science that finds a correlation between changes in antibody response that are small relative to natural variability. As the Agency for Toxic Substances and Disease Registry (ATSDR) noted in 2023, “it is well known that, in a normal vaccine response, there is already a wide distribution in the levels of titers considered normal. Changes of 30% or more in antibody titers can be within normal variations of IgG for the general population.” While it is natural to want to rely on the most protective level that has been identified in any study, an inappropriately protective approach may lead EPA to impose costly control measures that do not lead to actual health protection.

Leave a Reply

Your email address will not be published. Required fields are marked *